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Background
Determination of drug concentrations in plasma is the
gold standard for pharmacokinetic studies. However,
quantification of drug levels in dried blood spots (DBS)
obtained with a simple fingerprick is a patient-friendly
alternative in patient populations where intensive venous
sampling is unethical or impossible. Moreover, when
using DBS there is no need for plasma separation or cold
sample storage. Lastly, DBS can be stored or transported
without special requirements. The site of action of ralte-
gravir is within the infected cell. Intracellular drug levels
of raltegravir provide information on drug disposition in
a compartment where HIV replicates and may therefore be
useful in understanding its clinical pharmacology.
We here present the development, validation and applica-
tion of a sensitive and fast assay for the determination of
raltegravir in plasma, DBS and peripheral blood mononu-
clear cell (PBMC) lysate by means of liquid chromatogra-
phy coupled with electrospray tandem mass spectrometry
(LC-MS/MS). The assay allowed detection of the main
metabolite, raltegravir-glucuronide.
Methods
Raltegravir was extracted from plasma by means of pro-
tein precipitation using only 50 μL plasma. Extraction
from DBS was performed with a simple one-step extrac-
tion with a mixture of methanol, acetonitrile and 0.2 M
zinc sulphate in water and extraction from cell lysate was
performed in 50% methanol in water. Chromatographic
separation was performed on a reversed phase C18 col-
umn (150 × 2.0 mm, particle size 5 μm) with a stepwise
gradient using an acetate buffer (pH 5) and methanol, at
a flow rate of 0.25 mL/min. The analytical run time was
only 10 minutes. The triple quadrupole mass spectrome-
ter was operated in the positive ion-mode and multiple
reaction monitoring was used for drug quantification. The
method was validated over a range of 50 to 10,000 ng/mL
in plasma and DBS and a range of 1 to 500 ng/mL in
PBMC lysate. Dibenzepine was used as the internal stand-
ard.
Summary of results
The method was proven to be specific, accurate, precise
and robust. Method accuracy was within 85%–115% and
method precision (RSD) was less than 15% across all con-
centration ranges tested.
Conclusion
The described method has been applied in a clinical study
in patients on a raltegravir-containing salvage regimen.
DBS sampling proved to be easily implemented and DBS
samples were succesfully obtained from all included
patients.
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